Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase by Schietinger, Andrea et al.
Article
The Rockefeller University Press  $30.00
J. Exp. Med. Vol. 207 No. 11  2469-2477
www.jem.org/cgi/doi/10.1084/jem.20092450
2469
Activated CD8+ T cells can kill cancer cells   
directly by recognizing specific peptide–MHC 
complexes on the surface of the cancer cells. 
However, cancers can escape direct killing 
through down-regulation or loss of MHC or 
antigen targets, thus evading CTL-mediated de-
struction (Momburg et al., 1986; Smith et al., 
1988; Andersson et al., 1991; Kaklamanis et al., 
1992; Marincola et al., 2000; Vago et al., 2009). 
Cancer cells are embedded in tissue comprised 
of nonmalignant host cells and extracellular   
matrix, referred to as stroma. Furthermore, cancer   
cells are genetically diverse as a result of genomic 
instability and high mutation rate, and ulti-
mately, therapy-resistant cancer variants cause 
relapse and death. In contrast, stromal cells are 
nonmalignant and are generally genetically sta-
ble; although chromosomal abnormalities occur 
(Moinfar et al., 2000; Wernert et al., 2001;   
Matsumoto et al., 2003; Allinen et al., 2004; 
Fukino et al., 2007; Patocs et al., 2007), they are 
rare and do not show the clonality characteristic 
of cancer cells (Qiu et al., 2008). Therefore, 
when stromal cells are targeted for destruction 
by chemo-, radiation, and/or immunotherapy, 
there is no escape of variant stromal cells. In ad-
dition, stromal cells have tumor-promoting and 
immunosuppressive effects, making them thera-
peutic targets of interest.
Previously, we showed that in certain ex-
perimental settings, T cells could eradicate or 
arrest growth of large established tumors, in-
cluding cancer cell variants, by targeting stromal 
cells in the tumor: nonmalignant stromal cells 
pick up cancer antigens released by cancer cells, 
present antigenic epitopes on their surface MHC   
molecules,  and  become  targets  for  T  cells   
(Spiotto  et  al.,  2004;  Spiotto  and  Schreiber, 
2005; Zhang et al., 2007). This stromal destruc-
tion then leads to bystander killing of cancer 
cells (Spiotto et al., 2004; Spiotto and Schreiber, 
2005; Zhang et al., 2008). These studies used 
adoptively  transferred,  preactivated  CD8+  
T cells from TCR transgenic mice as effectors, 
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Cancers frequently evade cytotoxic T lymphocyte–mediated destruction through loss or 
down-regulation of tumor antigens and antigen-presenting major histocompatibility com-
plex molecules. Therefore, we have concentrated our efforts on immunological strategies 
that destroy nonmalignant stromal cells essential for the survival and growth of cancer 
cells. In this study, we developed a non–T cell receptor transgenic, immunocompetent 
tumor model to determine whether tumor-bearing hosts’ own immune systems could elimi-
nate cancer cells through stromal targeting and what role CD4+ T cells play alongside  
CD8+ T cells in this process. We found that aggressive cancers could be eradicated by T cell 
targeting of tumor stroma. However, successful elimination required the cooperation of 
CD4+ and CD8+ T cells not only during the induction phase but also during the effector 
phase in the tumor microenvironment, implying a new role for CD4+ T cells that has not 
been previously described. Our study demonstrates the potential of stromal targeting as a 
cancer immunotherapy and suggests that successful anticancer strategies must facilitate 
cooperation between CD4+ and CD8+ T cells at the right times and the right places.
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minimal  hen  egg  lysozyme  (HEL)  epitope  HEL(52–61) 
DYGILQINSR (Allen et al., 1987; Nelson et al., 1996; Carson 
et al., 1997). SIY is presented on H-2Kb and recognized by 
TCR transgenic 2C T cells (Sha et al., 1988), whereas HEL 
is presented on I-Ak and recognized by TCR transgenic 3A9 
T cells (Fig. 1 A; Ho et al., 1994). Ag104A expresses H-2Kk 
but does not express H-2Kb or I-Ak and remains MHC class II 
negative even after 48 h of in vitro IFN- treatment (Fig. 1 B, 
top) or in vivo (Fig. 1 B, bottom). Thus, neither the SIY nor 
HEL antigen can be presented directly on the surface MHC 
of Ag104A cancer cells. However, CD11b-negative stromal 
cells from B6C3 mice (mostly fibroblasts) are H-2Kb positive, 
and  CD11b-positive  stromal  cells  (mostly  monocytes  and 
macrophages) express H-2Kb and I-Ak. Thus, T cells can only 
recognize the SIY or HEL antigens if they are cross-presented 
on the surface MHC of host stromal cells. Two antigen- 
encoding vectors were constructed: (1) a gene encoding the 
trimeric peptide (SIYRYYGL-AAY)3 fused to the enhanced 
CFP (ECFP)–encoding sequence and (2) a gene encoding the 
25-mer peptide sequence [N44RNTDGSTDYGILQINSRW-
WCNDGR68] containing the known stimulatory HEL(52–61) 
epitope fused to the enhanced GFP (EGFP)–encoding se-
quence (Fig. 1 C). Using these two constructs, we established 
Ag104A  tumor  cell  lines  expressing  the  CD8+  T  cell– 
recognized SIY antigen (A-SIY), the CD4+ T cell-recognized 
HEL antigen (A-HEL), or both the SIY and HEL antigens 
(A-SIY/HEL; Fig. 1 D).
To determine whether the SIY and HEL antigens were 
released from transduced Ag104A cells and cross-presented 
by B6C3-derived host cells, we used proliferation of naive 
TCR transgenic CD8+ and CD4+ T cells in vivo as a readout 
of antigen uptake and presentation by host cells. B6C3 mice 
were inoculated with A-HEL, A-SIY, or A-SIY/HEL cancer 
cells. 24 h later, CFSE-labeled naive CD8+ 2C T cells or 
CD4+ 3A9 T cells were adoptively transferred into the inoc-
ulated mice, and 5 d later, draining lymph nodes were reiso-
lated to analyze proliferation of adoptively transferred T cells 
(Fig. 1 E). CFSE-labeled 2C T cells proliferated in lymph 
nodes draining inocula of A-SIY or A-SIY/HEL cancer cells 
but not in lymph nodes draining inocula of A-HEL cancer 
cells, whereas 3A9 T cells proliferated in lymph nodes drain-
ing inocula of A-HEL or A-SIY/HEL cancer cells but not in 
those draining inocula of A-SIY cancer cells. Thus, in B6C3 
mice, antigen-presenting host cells cross-presented SIY and 
HEL antigens released from the transduced Ag104A cancer 
cells, inducing proliferation of antigen-specific T cells.
Coexpression of SIY and HEL antigen is required  
for the bystander elimination of cancer cells
Once we had established that SIY and HEL antigen could be 
released from Ag104A and presented on host cells, we inves-
tigated whether endogenous, nontransgenic T cells could tar-
get antigens on tumor stromal cells and cause bystander 
destruction of cancer cells. Naive B6C3 mice were injected 
with A-SIY, A-HEL, or Ag104A cells overexpressing only 
EGFP as control (A-EGFP). We used a high injection dose, 
and  the  tumor-bearing  recipients  were  immunodeficient; 
therefore, the role of CD4+ T cells was not examined. CD4+ 
T cells are essential during the induction phase and for memory 
formation of CD8+ T cells (Keene and Forman, 1982; Hung 
et al., 1998; Hu et al., 2000; Gao et al., 2002; for reviews see 
Toes  et  al.,  1999;  Castellino  and  Germain,  2006).  CD4+  
T cells adoptively transferred into SCID, Rag-KO, or sub-
lethally irradiated or lymphodepleted WT mice can up-regulate 
MHC class II expression on cancer cells for direct targeting 
(Muranski et al., 2008), amplify CD8+ T cells that directly   
target cancer cells (Greenberg et al., 1981), or eradicate MHC 
class II–negative cancer cells without CD8+ T cells (Greenberg 
et al., 1985; Frey, 1995; Monach et al., 1995; Mumberg et al., 
1999; Perez-Diez et al., 2007) through IFN- effects on host 
stroma (Monach et al., 1995; Qin and Blankenstein, 2000; 
Egilmez et al., 2002; Broderick et al., 2005; Muranski et al., 
2008), and CD4+ T cells have long been implicated in the ac-
tivation of macrophages and other nonlymphoid tumoricidal 
effector cells (Greenberg, 1991; Hung et al., 1998).
Given the potential clinical application of stromal target-
ing in immunotherapy, especially in treating cancers that are 
prone to immune evasion, we thought it was important to 
test the efficacy of stromal targeting (recognition of cross-
presented antigen on stromal cells by T cells) in a nontrans-
genic T cell model using immunocompetent mice. Therefore, 
the objective of the present study was twofold: (1) to use a 
physiologically relevant model to determine whether a nor-
mal host without prior immunization could eliminate cancer 
cells through stromal targeting and (2) to determine what role 
CD4+ T cells play alongside CD8+ T cells in killing cancer 
cells as bystanders in the tumor microenvironment. We ana-
lyzed immune responses of normal immunocompetent mice 
in which the T cells were host derived and activated by the 
cancer cells in the host. We used a highly aggressive cancer 
cell line derived from a spontaneous tumor, Ag104A, and 
engineered it to express defined CD4+ and CD8+ T cell– 
recognized epitopes. These epitopes cannot be presented by 
the cancer cells directly because Ag104A lacks the appropri-
ate MHC molecules. Nevertheless, we found that normal 
hosts, without preimmunization, generated T cells that suc-
cessfully eliminated tumors through stromal targeting. Sur-
prisingly, CD4+ T cells were needed not only for optimal 
CD8+ T cell activation but also at the effector stage within 
the tumor microenvironment.
RESULTS
Cancer cells express tumor antigens that  
are cross-presented by host-derived cells  
to antigen-specific CD4+ or CD8+ T cells
Ag104A is a highly aggressive cancer cell line that arose spon-
taneously in an aging mouse. Ag104A cancer cells injected 
subcutaneously produce tumors of 2 cm3 within 30 d in 
immunocompetent C57BL/6 × C3H/HeN F1 mice (B6C3; 
Wick et al., 1997; Yu et al., 2004). Ag104A cells were trans-
duced  to  express  the  CD8+  T  cell–recognized  epitope   
SIYRYYGL  (SIY)  and/or  the  CD4+  T  cell-recognized   JEM VOL. 207, October 25, 2010 
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of CD4+ and CD8+ T cell–recognized tumor antigens on the 
same cancer cell could delay or prevent tumor growth. B6C3 
mice were challenged with 5 × 105 A-SIY/HEL cancer cells. 
Of note, A-SIY/HEL cancer cells express only half the amount 
of the SIY and HEL antigen in comparison with single   
antigen–expressing  A-SIY  or  A-HEL  (Fig.  1  D).  Although 
small tumors initially developed within 2–3 wk to a volume of 
20–40 mm3, they then regressed completely, and the mice re-
mained tumor-free for >2 yr (Fig. 3).
Because it was possible that stromal targeting might not 
completely eradicate cancer cells but instead arrest their prolif-
eration, resulting in dormancy or an equilibrium state (Zhang 
et al., 2008), we treated these tumor-free mice with four doses 
of a CD4+ T cell–depleting antibody and three doses of a 
CD8+ T cell–depleting antibody. Although both effector and 
memory CD8+ T cells have been shown to be effectively de-
pleted by antibody treatment (Zhang et al., 2008), memory 
CD4+ T cell depletion is inefficient compared with naive 
5 × 105 Ag104A cells, a dose which is 50-fold higher than the 
100% lethal dose of 104 Ag104A parental cancer cells. There 
were no differences in tumor outgrowth between A-EGFP, 
A-SIY, or A-HEL (Fig. 2 A), and all tumors grew progres-
sively, killing the host within weeks. Thus, high level expres-
sion of either CD4+ or CD8+ T cell–recognized tumor 
antigens alone is not sufficient to allow endogenous CD4+ or 
CD8+ T cells to target tumor stroma and prevent tumor out-
growth. We also injected A-SIY and A-HEL into the same 
mouse on opposite flanks (Fig. 2 B). Again, both tumors 
grew progressively with similar growth kinetics.
CD4+ T cells have been shown to be important for efficient 
CD8+ T cells responses through promotion of CD8+ T cell 
proliferation and clonal expansion, induction of effector func-
tion, and generation of long-lived memory. Because the pres-
ence  of  tumor-derived  CD4+  or  CD8+  T  cell–recognized 
antigen in the same mouse but on opposite flanks had no impact 
on outgrowth, we next asked whether simultaneous expression 
Figure 1.  Cancer cells express tumor 
antigens that are cross-presented and 
activate TCR transgenic antigen-specific 
CD4+ or CD8+ T cells. (A) Model of indirectly 
presented CD4+ or CD8+ T cell–recognized 
tumor antigens. Ag104A cancer cells, which 
lack the necessary MHC molecules to directly 
present the CD8+ T cell–recognized SIY pep-
tide and the CD4+ T cell–recognized HEL pep-
tide, release these antigens into the 
surrounding stroma where they are picked up 
by macrophages, dendritic cells, and other 
stromal cells and are presented on their sur-
face MHC. Antigen-specific T cells recognize 
the cross-presented antigens on stromal cells. 
(B, top) In vitro cultured Ag104A cancer cells 
were cultured where indicated for 48 h with 
IFN- and stained with PE-conjugated anti-
bodies specific for the indicated MHC mol-
ecule (right of histogram). (bottom) Ag104A 
cancer cells isolated from established tumors 
in vivo (identified by positive surface staining 
for an Ag104A tumor-specific antigen recog-
nized by the monoclonal antibody 237mAb) 
were stained with the indicated antibodies. 
Histograms were gated on 237mAb-positive 
cells. Similar results were obtained in two 
additional experiments. (C) Schematic dia-
gram of the CD4+ and CD8+ T cell–recognized 
antigens. The CD8+ T cell–recognized epitope 
SIYRYYGLAAY (3× repeat) was fused to ECFP. 
The CD4+ T cell–recognized epitope HEL  
(25 mer) was fused to EGFP and flanked  
by a 6xHis tag. (D) Fluorescence intensity of 
Ag104A tumor cell lines transduced to express 
SIY-ECFP (A-SIY), HEL-EGFP (A-HEL), or both 
(A-SIY/HEL). Numbers indicate the mean fluorescence intensity (MFI). Untransduced Ag104A cells (A-WT) are included for comparison. (E) Indicated cancer 
cell suspensions were injected subcutaneously into the lower back of B6C3 mice. 24 h later, naive CFSE-labeled 2C and HEL transgenic T cells were adop-
tively transferred intravenously. 5 d later, draining lymph nodes were reisolated, and CFSE dilution was analyzed. CFSE plots were generated by gating on 
CD4+ (3A9)- or CD8+ (2C)-positive cells. Similar results were obtained in two additional experiments. SSC, side scatter.2472 T cell cooperation during attack on tumor stroma | Schietinger et al.
237mAb antigen, an antigen which has never been observed 
to be lost by Ag104A (Schietinger et al., 2006), and (c) nega-
tive for both the SIY and HEL antigens expressed by the ini-
tial inoculum. These results demonstrated that highly aggressive 
cancer cells could be completely eliminated by CD4+ and 
CD8+ T cells even though only host stromal cells were di-
rectly targeted. However, synergy of CD4+ and CD8+ T cells 
was required.
Given  that  the  presence  of  tumor-derived  CD4+  and 
CD8+ antigens in the same mouse (injection of A-SIY and   
A-HEL on opposite flanks; Fig. 2 B) had no effect on tumor 
outgrowth, whereas the A-SIY/HEL cancer cells were eradi-
cated (Fig. 3), we reasoned that copresentation of CD4+ and 
CD8+ T cell–recognized antigens in the tumor-draining 
lymph nodes was necessary for optimal tumor elimination.   
To further elucidate the spatial and temporal mechanics of 
CD4+/CD8+ T cell stromal targeting, we injected B6C3 mice 
with either A-SIY/HEL cancer cells (5 × 105) or with a mix-
ture of A-SIY (2.5 × 105) and A-HEL (2.5 × 105) cancer cells 
(A-SIY + A-HEL mix). Immunoblotting demonstrated that 
A-SIY/HEL and the A-SIY + A-HEL mix contained the 
same amount of antigen (Fig. 4 A). Thus, both inocula con-
tained the same number of Ag104A cells and the same quan-
tity of tumor antigens. The only difference was that in 
A-SIY/HEL, both antigens were expressed by each Ag104A 
cancer cell, whereas in the A-SIY + A-HEL mix, each antigen 
was expressed by half of the cells in the mixed cell inoculum. 
The same total amount of CD4+ and CD8+ T cell–recognized 
antigen should be cross-presented in the draining lymph   
nodes. Unexpectedly, the two inocula behaved very differently 
in vivo (Fig. 4 B). Although mice challenged with A-SIY/HEL 
remained tumor free for >2 yr, A-SIY + A-HEL mix tumors 
grew out progressively (Fig. 4 B) with growth rates similar to 
controls (A-EGFP, A-SIY, or A-HEL; Fig. 2 A). Microscopic 
analysis of A-SIY + A-HEL mix tumors at 2–3 wk showed 
that the growing tumors were not homogenous mixtures   
of A-SIY and A-HEL cancer cells, but rather had a mosaic   
appearance with large areas of either A-SIY–positive blue or 
A-HEL–positive green tumor (Fig. 4 C). The A-HEL areas of 
the tumor had very few A-SIY cells and vice versa. This finding 
CD4+ T cell depletion (Chace et al., 1994). However, given 
that HEL-specific CD4+ T cells do not cause tumor regression 
in the absence of CD8+ T cells in our model, effective CD8+ 
T cell depletion should lead to outgrowth of any remaining 
A-SIY/HEL cancer cells. Only 1 of the 20 mice developed a 
tumor near but not at the site of previous tumor inoculation. 
Subsequent analysis of this tumor revealed that it was not 
caused by outgrowth of the previous A-SIY/HEL inoculum 
but was in fact a new spontaneous tumor: the reisolated cancer 
cells were (a) positive for H-2Kb and Db in addition to H-2Kk 
MHC class I molecules, indicating that the tumor arose from 
B6C3 hybrid cells, (b) negative for the Ag104A-specific 
Figure 2.  High expression of either SIY or 
HEL tumor antigen is insufficient to prevent 
tumor outgrowth. (A) 5 × 105 A-SIY (n = 4), A-HEL 
(n = 4), or A-EGFP (n = 4) cells were injected sub-
cutaneously into B6C3 mice. Tumor volume was 
monitored. Data are representative of at least five 
independent experiments. (B) Mice were inocu-
lated with A-SIY cells on one flank and A-HEL 
cells on the contralateral flank (n = 4). Tumor 
volume was monitored. Data are representative  
of two independent experiments. (A and B) Error 
bars show SEM.
Figure 3.  Cancer cells coexpressing CD8+ and CD4+ antigens are 
rejected. Mice were injected with either 5 × 105 A-EGFP control (n = 3) or 
5 × 105 A-SIY/HEL (n = 5) cancer cells coexpressing both the SIY and HEL 
antigens. Tumor volume was monitored. The inset shows small tumors  
(40 mm3) that initially developed but then regressed completely. Error bars 
show SEM. A-SIY/HEL recipient mice remained tumor free for >2 yr.  
These mice were then treated four times with the CD4-depleting antibody 
GK1.5 and three times with the CD8-depleting antibody YTS196 over a  
3-mo interval. Even after administration of antibodies, all mice remained 
tumor free. Data are representative of at least four independent experi-
ments (*, P < 0.0001).JEM VOL. 207, October 25, 2010 
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and  prevent  out-
growth by the mixed 
tumor.  After  21  d, 
A-SIY/HEL tumors 
again  were  elimi-
nated or very small; however, A-SIY + A-HEL mix tumors 
grew progressively on the contralateral flank. This result sug-
gests that for bystander elimination of cancer cells, synergy of 
CD4+ and CD8+ T cells is also required during the effector 
phase in the local tumor stroma.
A-SIY + A-HEL mix tumors were reisolated from mori-
bund mice, readapted to culture, and analyzed for the presence 
of Ag104A expressing SIY or HEL (Table I). We found that 
>98% of the cancer cells were HEL positive with almost com-
plete elimination of SIY-positive cancer cells. The same selec-
tion against SIY-positive cancer cells occurred in mice that had 
not received A-SIY/HEL in the opposite flank, suggesting that 
A-SIY + A-HEL mix cancer cells also induced effective sys-
temic anti-SIY immune responses (Table I). Thus, there was no 
evidence that A-SIY/HEL cancer cells were more effective in 
inducing anti-SIY–specific CD8+ T cell responses than A-SIY + 
A-HEL mix tumors. Because the aforementioned experi-
ments demonstrated a selection against SIY-expressing cancer 
cells,  we  tested  whether  the  systemic  response  induced  by   
A-SIY/HEL was sufficient to eliminate A-SIY tumors. When 
mice were injected on one flank with A-SIY/HEL cancer cells 
and A-SIY on the opposite side, 5/5 mice rejected A-SIY/
HEL tumors; however, 3/5 mice developed progressive contra-
lateral A-SIY tumors (Fig. 5 A and Table I). We reisolated and 
analyzed the A-SIY tumors for SIY expression, and all of the 
tumors retained the SIY antigen (Table I); thus, the anti-SIY 
immune response induced by A-SIY/HEL inocula was not 
sufficient to prevent A-SIY tumor outgrowth in mice. Similarly, 
when mice were injected on one flank with A-SIY/HEL can-
cer cells and A-HEL on the opposite site, A-SIY/HEL tumors 
that mixed cancer cells grew as mosaic tumors was demon-
strated previously and is explained by the fact that after cancer 
cells are inoculated as cell suspensions, many of the inoculated 
cancer cells die after injection (Schreiber et al., 2006), and sub-
sequently, individual cells expand clonally, creating small 
pockets of each cancer cell clone. In spite of the mosaicism, 
overall, the tumor had a 50:50 mix of A-SIY and A-HEL   
cancer cells; therefore, the amount of SIY and HEL antigen in 
draining lymph nodes was the same as that in draining lymph 
nodes from A-SIY/HEL tumors.
Cooperation of CD4+ and CD8+ T cells is required during  
the effector phase in the local tumor microenvironment
Because similar amounts of antigen entered the draining lymph 
node whether coming from A-SIY + A-HEL mix or A-SIY/
HEL, both inocula should have induced similar activation/ 
proliferation of HEL-specific CD4+ T cells and SIY-specific 
CD8+  T  cells.  However,  Mitchison  and  O’Malley  (1987) 
showed that CD4+ and CD8+ T cell epitope linkage enhances 
cytolytic responses in vivo when antigens are present in low 
concentration. At low antigen concentrations, APCs may pick 
up one or the other antigen but not both, whereas at high con-
centrations, most APCs will pick up both antigens, even when 
they are not linked (or derived from the same cell). Therefore, 
the antitumor response to A-SIY/HEL could be explained by 
enhanced activation and proliferation of CD4+ and CD8+  
T cells during the induction phase because in A-SIY/HEL, 
both antigens were present in the same cell. To clarify the role 
of CD4+ T cells during the induction stage versus the effector 
stage, we injected A-SIY/HEL cancer cells into one flank and 
the mixture of A-SIY and A-HEL cancer cells into the oppo-
site flank of the same mouse (Fig. 4 D). If the requirement for 
CD4+ T cell help was solely during induction, CD4+ and 
CD8+ T cells optimally induced by the A-SIY/HEL inoculum 
should circulate, enter the A-SIY + A-HEL mix cancer cells, 
Figure 4.  CD4+ and CD8+ T cell-recognized 
antigens must be expressed in the same 
cancer cell during the effector phase.  
(A) Lysates from 105 cell equivalents of  
A-SIY/HEL, A-SIY, and A-HEL cancer cells were 
analyzed by immunoblotting with anti-EGFP. 
A mixture of 5 × 104 A-SIY and 5 × 104 A-HEL 
cells was also analyzed. (B) 2.5 × 105 A-SIY 
were mixed with 2.5 × 105 A-HEL and injected 
subcutaneously into B6C3 mice (n = 4).  
5 × 105 A-SIY/HEL cancer cells were injected 
subcutaneously into other B6C3 mice (n = 6). 
Tumor volume was monitored. Error bars 
show SEM. Data are representative of five 
independent experiments (*, P = 0.0052).  
(C) Confocal fluorescence microscopy images 
of frozen tumor tissue sections of early  
(<2 wk old) A-SIY+HEL-mix tumors. Green indi-
cates HEL-EGFP; blue indicates SIY-ECFP. Each 
panel shows a different region of a tumor. 
Bars, 200 µm. (D) 2.5 × 105 A-SIY and 2.5 × 105 
A-HEL cells were mixed and injected sub-
cutaneously into one flank, and 5 × 105  
A-SIY/HEL cancer cells were injected into the 
opposite flank of B6C3 mice (n = 5). Tumor 
volume was monitored. Error bars show  
SEM (*, P = 0.0023).2474 T cell cooperation during attack on tumor stroma | Schietinger et al.
with A-SIY/HEL cells. Only 1/10 inocula of A-HEL and   
A-SIY/HEL cancer cells and 2/10 inocula of A-SIY and   
A-SIY/HEL cancer cells formed small tumors (Fig. 6, bottom).
These results are in contrast to those seen with the A-SIY + 
A-HEL mix tumors in which large tumors developed that 
consisted of >90% A-HEL. The mix tumor is analogous to a 
tumor made up of two different ALVs without any parental 
cancer cells expressing both the CD4+ and CD8+ T cell anti-
gens. Because both antigens could be presented in the draining 
lymph nodes, a CD8+ T cell response was induced that could 
eliminate most of the A-SIY cancer cells, but because these are 
mosaic tumors (Fig. 4 C), the lack of consistent, concomitant 
CD4+ T cell antigen throughout the tumor meant that the 
immune response was not sufficient to prevent outgrowth of 
the CD8+ T cell ALV (A-HEL). Because ALVs arise from ex-
pansion of mutated clones within the parental tumor, this sce-
nario in which the tumor starts with two ALVs and no parental 
cancer cells is unlikely. But even when 50% of the tumor con-
sisted of cancer cells lacking CD4+ or CD8+ T cell antigens or 
both antigens (Fig. 6), concomitant expression of CD4+ and 
CD8+ T cell antigens in the other 50% of the cancer cells was 
sufficient to prevent or control their growth.
DISCUSSION
In conclusion, we have shown that aggressive cancer cells 
lacking MHC molecules for direct presentation can be eradi-
cated by antigen-specific T cell targeting tumor stroma, and 
thus immune stromal targeting has enormous potential as a 
tool for cancer immunotherapy. Stromal cells do not mutate 
to evade detection but can present tumor antigens, making 
them T cell targets and resulting in bystander destruction of 
cancer cells. Using naive, immunocompetent hosts, we found 
that this bystander killing of cancers through stromal targeting 
were rejected, whereas all of the contralateral A-HEL tumors 
grew progressively (Fig. 5 B), retaining the HEL antigen. The 
A-SIY tumors that did grow out (3/5) grew at a slower rate 
than the A-HEL tumors (Fig. 5, A and B), thus the A-SIY/HEL 
inoculum  induced  a  systemic  anti-SIY  response.  However, 
without the presence of the HEL antigen in the cancer cells, 
stromal targeting and tumor elimination was insufficient. Col-
lectively, these results demonstrate that for optimal stromal tar-
geting, cooperation of CD4+ T cells and CD8+ T cells is not 
only required during the induction phase but also during the 
effector phase in the local tumor microenvironment.
CD4+ and CD8+ T cells eliminate antigen-loss variants 
(ALVs) embedded in the tumor microenvironment of  
A-SIY/HEL cancer cells
Cancer cells can evade immune-mediated destruction through 
mechanisms such as down-regulation of MHC or antigen-
processing machinery. Another strategy is down-regulation or 
deletion of the targeted tumor antigens. The escape of ALVs is 
a major obstacle to T cell–based immunotherapy for cancer. 
Because the indirect destruction of A-SIY/HEL cancer cells 
was so powerful, we asked whether stromal targeting coordi-
nated by CD4+ T cells and CD8+ T cells would eliminate 
ALVs embedded within the tumor stroma. Thus, naive B6C3 
mice were injected with subcutaneous inocula of 2.5 × 105 
Ag104A cancer cells (A-WT) either alone or mixed with   
2.5 × 105 A-SIY/HEL cancer cells. As shown in Fig. 6 (top),   
A-WT inocula alone (8/8) grew progressively and killed the 
host within 4 wk. However, when A-WT cells were mixed 
with A-SIY/HEL cancer cells, tumor growth was significantly   
repressed, and tumors did not exceed a tumor volume of   
250 mm3 after 28 d. Only 3/10 inocula developed larger tumors 
at later times. We also tested mixtures of A-HEL or A-SIY 
Table I.  Expression of SIY and HEL antigens on reisolated tumors
Inoculation on side A Inoculation on side B Animal number Tumor on side B
Days of growth Volume Antigen expression (% of tumor 
cells positive)
SIY only HEL only
mm3 % %
Experiment I
A-SIY/HEL A-SIY + A-HEL 1 21 2,600 <1 93
A-SIY/HEL A-SIY + A-HEL 2 21 1,950 <1 96
A-SIY/HEL A-SIY + A-HEL 3 21 4,900 <1 89
A-SIY/HEL A-SIY + A-HEL 4 21 2,600 <1 95
None A-SIY + A-HEL 1 18 1,300 <1 94
None A-SIY + A-HEL 2 18 1,200 <1 95
Experiment II
A-SIY/HEL A-SIY 1 26 520 80 NA
A-SIY/HEL A-SIY 2 26 644 83 NA
A-SIY/HEL A-SIY 3 29 520 82 NA
NA, not applicable. 5 × 105 A-SIY/HEL or A-SIY cancer cells or 2.5 × 105 A-SIY mixed with 2.5 × 105 A-HEL cancer cells were injected subcutaneously into opposite flanks of 
B6C3 mice as indicated. Tumor growth was monitored. Tumors on side B were readapted to culture and analyzed by flow cytometry for expression of the SIY and HEL 
antigens. Data are representative of at least two independent experiments.JEM VOL. 207, October 25, 2010 
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monokine induced by IFN-, and/or IP-10. Although this 
study has demonstrated bystander killing of cancer cells express-
ing tumor-specific antigens, it is likely that this mechanism of 
cancer cell elimination is also applicable to cancers expressing 
immunogenic self-antigens. Nonetheless, our results suggest 
that cancer immunotherapy strategies targeting stroma by T cells 
must ensure that CD4+ T cells provide help for CD8+ T cells 
during the effector phase in the tumor microenvironment.
MATERIALS AND METHODS
Mice and cell lines. Ag104A, a spontaneous fibrosarcoma isolated from an 
aging mouse (female, C3H/HeN), was previously described (Ward et al., 
1989) and is recognized by the tumor-specific monoclonal antibody 237mAb 
(Ward et al., 1989; Schietinger et al., 2006). B6C3 F1 mice were obtained 
from Charles River, 2C Rag1/ mice were provided by J. Chen (Massa-
chusetts Institute of Technology, Cambridge, MA), and HEL transgenic 
mice (TgN[TcrHEL3A9]Mmd) were obtained from The Jackson Labora-
tory. All mice were maintained in a specific pathogen-free barrier facility at 
the University of Chicago in accordance with the Institutional Animal Care 
and Use Committee guidelines.
Flow cytometric analysis. Flow cytometric analysis was performed using 
FACSCalibur, FACScan, LSRII, and DakoCytomation CyanADP and   
analyzed with FlowJo software (BD). Cells were sorted using Cytomation 
MoFlo HTS (Dako) and FACS Aria (BD).
Antibodies, plasmids, and retroviral infections. Anti-EGFP monoclo-
nal antibody (clone JL-8; BD) was used for immunoblotting. PE-anti–mouse 
requires the cooperation of CD4+ and CD8+ T cell not only 
during the induction phase, but during the effector phase. Al-
though the role of CD4+ T cells in immune induction and 
memory T cell formation has been extensively studied, only   
recently was it shown that CD4+ T cells are also important in 
mobilizing effector CTL to the peripheral sites of infection   
(Nakanishi et al., 2009). The study presented here together with 
the findings of Nakanishi et al. (2009) reveal that CD4+ T cell 
help is not only restricted to priming or memory formation of 
CD8+ T cells and imply a new role for CD4+ T cells for the ef-
fector phase that has not been previously described. The exact 
role of CD4+ T cells during the effector phase in our tumor 
model remains to be elucidated. It is possible that the coopera-
tion of CD8+ and CD4+ T cell during the effector phase leads 
to direct killing of stromal cells cross-presenting the antigen, 
which could result in the destruction of cancer cells as bystanders. 
Another equally plausible explanation is that T cell–stromal cell 
interactions lead to the release of IFN- and TNF that then act 
on the stroma and/or the cancer cells directly or indirectly, for 
example by the induction of inducible nitric oxide synthase, 
Figure 5.  Insufficient systemic immune responses are induced in 
mice rejecting A-SIY/HEL cancers. (A) 5 × 105 A-SIY and 5 × 105 A-SIY/
HEL cancer cells were injected into opposite flanks of B6C3 mice (n = 5). 
Tumor volume was monitored. Each line represents an individual mouse. 
Although 2/5 mice rejected the contralateral A-SIY inocula, 3/5 mice 
showed progressive growth of A-SIY tumors, albeit at a slower rate than 
A-SIY tumors growing in mice without a contralateral A-SIY/HEL inocula 
(*, P = 0.0449 vs. A-SIY without contralateral A-SIY/HEL inocula). The 
three A-SIY tumors were readapted to culture, and a summary of the flow 
analysis is shown in Table I (experiment II). Data are representative of two 
independent experiments. (B) 5 × 105 A-SIY/HEL and 5 × 105 A-HEL cancer 
cells were injected into opposite flanks of B6C3 mice (n = 4). Tumor vol-
ume was monitored. Error bars show SEM (*, P = 0.0007). Data are repre-
sentative of two independent experiments.
Figure 6.  ALVs lacking the SIY and HEL antigens are arrested or 
eliminated when mixed with A-SIY/HEL cancer cells in the same 
inoculum. (top) Naive B6C3 mice received bilateral subcutaneous inocula 
of 2.5 × 105 Ag104A WT (A-WT) cells either alone (n = 4) or mixed with  
A-SIY/HEL cancer cells (n = 5). (bottom) Mice received A-HEL (n = 5) or A-SIY 
(n = 5) mixed with A-SIY/HEL cancer cells. Tumor growth was monitored. 
Each line represents an individual mouse (*, P < 0.0001 vs. A-WT alone). 
Data are representative of two independent experiments.2476 T cell cooperation during attack on tumor stroma | Schietinger et al.
Confocal microscopy. EGFP (HEL antigen) and ECFP (SIY antigen)   
fluorescence of tumors (15–20-µm frozen sections) were imaged with a 
spectral 2-photon confocal microscope (SP5 AOBS; Leica).
Statistical analyses. Statistical analyses were performed with Prism version 
5.0 (GraphPad Software, Inc.) using unpaired two-tailed Student’s t tests.   
A p-value of <0.05 was considered statistically significant.
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